Ultrafast CT developer Imatron of South San Francisco, CA, saidlast week that it has completed a $16 million private equity placementfor its HeartScan Imaging subsidiary, which operates ultrafastCT-based imaging centers. The infusion will help Imatron
Ultrafast CT developer Imatron of South San Francisco, CA, said
last week that it has completed a $16 million private equity placement
for its HeartScan Imaging subsidiary, which operates ultrafast
CT-based imaging centers. The infusion will help Imatron establish
HeartScan as a separate business that will purchase Imatron scanners.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.